Is Quizartinib available in China?

Quizartinib (Quizartinib, trade name Vanflyta) is a targeted therapy for acute myeloid leukemia (AML) patients with FLT3 (FMS-like tyrosine kinase 3) internal tandem duplication (ITD) mutations. FLT3 mutation is one of the most common mutations in AML and is closely associated with poor prognosis. Quizartinib, as a second-generation FLT3 inhibitor, inhibits FLT3 kinase activity and prevents receptor autophosphorylation, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation.

Quizatinib is an oral, small molecule tyrosine kinase inhibitor with good bioavailability. It is approved for use in combination with standard cytarabine and anthracyclines for induction and consolidation therapy in adult patients with newly diagnosed FLT3-ITD-positive AML, and as maintenance monotherapy after consolidation chemotherapy. Clinical trials have shown that quizartinib can significantly extend the progression-free survival and overall survival of patients, and improve the complete remission rate of patients.

The recommended dose of quizartinib varies according to the treatment phase, including different dosage regimens during the induction phase, consolidation phase and maintenance phase. However, quizartinib is also associated with certain adverse reactions, such as nausea, vomiting, diarrhea, fatigue, headache, etc., as well as possible electrocardiogram abnormalities. Therefore, it is necessary to closely monitor the patient's response during use and adjust the treatment plan in a timely manner.

Currently, Quizartinib is not currently on the market in China. We hope that Quizartinib will be launched in the country soon. The launch of Quizartinib provides a new treatment option for FLT3-ITD-positive AML patients, marking an important progress in the field of AML treatment. However, its price is relatively high and may not be suitable for all patients in some cases, such as patients with severe hypokalemia, severe hypomagnesemia, etc. Therefore, before using quizartinib, doctors need to conduct a comprehensive assessment of the patient's specific situation and develop an individualized treatment plan.

xa0

Reference materials:https://go.drugbank.com/drugs/DB12874